Characteristics of subtype III-A CRISPR-Cas system in Mycobacterium tuberculosis: An overview

• Published in: Infection, genetics and evolution Vol. 112; p. 105445
• Main Authors: Hamdi, Insaf, Boni, Funmilayo, Shen, Qinglei, Moukendza, Liadrine, Peibo, Li, Jianping, Xie
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.08.2023
• Subjects: adaptive immunity; Antitubercular Agents - metabolism; Bacteriophages - genetics; CRISPR-Cas III-A; CRISPR-Cas Systems; CRISPRi; evolution; Housekeeping nuclease-anti-CRISPR; infection; Mycobacterium tuberculosis; Mycobacterium tuberculosis - genetics; pathogens; plasmids; Plasmids - genetics; Reverse transcriptase (RT); RNA-directed DNA polymerase; Reverse transcriptase (RT); Mycobacterium tuberculosis; CRISPRi; CRISPR-Cas III-A; Housekeeping nuclease-anti-CRISPR
• ISSN: 1567-1348; 1567-7257; 1567-7257
• DOI: 10.1016/j.meegid.2023.105445

CRISPR-Cas systems are the only RNA- guided adaptive immunity pathways that trigger the detection and destruction of invasive phages and plasmids in bacteria and archaea. Due to its prevalence and mystery, the Class 1 CRISPR-Cas system has lately been the subject of several studies. This review highlights the specificity of CRISPR-Cas system III-A in Mycobacterium tuberculosis, the tuberculosis-causing pathogen, for over twenty years. We discuss the difference between the several subtypes of Type III and their defence mechanisms. The anti-CRISPRs (Acrs) recently described, the critical role of Reverse transcriptase (RT) and housekeeping nuclease for type III CRISPR-Cas systems, and the use of this cutting-edge technology, its impact on the search for novel anti-tuberculosis drugs. •Overview of the last classification of type III CRISPR-Cas system.•Description of anti-CRISPRS and role of Reverse transcriptase (RT) and housekeeping nuclease in type III CRISPR-Cas system.•Comparison of subtype III-A in Mycobacterium tuberculosis complex.•Characteristics of subtype CRISPR III-A System in Mycobacterium tuberculosis H37Rv.•Impact of CRISPR interference on the search for novel anti-tuberculosis drugs.